PMCCPMCCPMCC

Search tips
Search criteria 

Advanced


 
Formats
Article sections
Authors
Related links
Logo of raretumorsLink to Publisher's site
 
Rare Tumors. 2012 June 26; 4(3): e46.
Published online 2012 September 20. doi:  10.4081/rt.2012.e46
PMCID: PMC3475953
©Copyright E. Mahe et al., 2012
Giant cell temporal arteritis associated with overlying basal cell carcinoma: co-incidence or connection?
Etienne Mahe,1 Dina El Demellawy,2,3 Anita Bane,1 and Salem Alowami1
1Department of Pathology and Molecular Medicine, Hamilton Health Sciences, McMaster University, Hamilton;
2Department of Pathology and Laboratory Medicine, William Osler Health Care;
3Northern Ontario School of Medicine, Brampto, Ontario, Canada
Correspondence: Etienne Mahe, Department of Pathology and Molecular Medicine, McMaster University Medical Centre, Room 2N10, 1200 Main St. West, Hamilton, ON, L8N 3Z5 Canada., Tel. Phone: +1.28.2423250, E-mail: etienne.mahe/at/medportal.ca
Contributed by
Contributions: DED, AB, SA, made the original diagnoses, contributed photomicrographs and performed the literature reviews; EM reviewed relevant clinical information and wrote the final manuscript.
Conflict of interests: the authors report no conflicts of interests.
Received December 21, 2011; Accepted April 23, 2012.
This work is licensed under a Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0).
Licensee PAGEPress, Italy
Abstract
Giant cell arteritis is a granulomatous vasculitis of large and medium sized arteries manifesting as temporal arteritis and/or polymyalgia rheumatica. The histological assessment of temporal artery biopsies is frequently encountered in anatomical pathology and has important diagnostic consequences in patients clinically suspected of having giant cell arteritis. We present an intriguing case of giant cell arteritis associated with a Basal cell carcinoma and discuss the ongoing controversy pertaining to the association of giant cell arteritis/polymyalgia rheumatica with malignancy.
Key words: giant cell arteritis, basal cell carcinoma.
Giant cell arteritis (GCA) is a systemic granulomatous vasculitis of large and medium sized arteries manifested either as a local temporal or cranial artertis (TA) or as polymyalgia rheumatica (PMR), an entity characterized by pain and stiffness of the shoulder and hip girdles or proximal extremities.1–3 The clinical features of TA usually include localized pain, often accompanied by jaw claudication; delay of appropriate treatment for TA carries a risk of ophthalmological and neurological complications.1–3 Notably, not all cases of GCA manifest with both TA and PMR; indeed, most cases of GCA manifest as PMR and many cases of TA do not present with other rheumatologic symptoms.4 Interestingly, whilst some authors have noted an association between PMR and malignancy,5,6 recent studies have questioned the association between histologically confirmed GCA (i.e. cases of TA) and malignancy.7–10 We present an intriguing case of basal cell carcinoma identified in the same biopsy specimen as GCA.
An eighty three year old male presented to his primary care physician with a left temporal non-traumatic, ulcerating lesion. In the three months prior to his presentation, he had also noted periodic intense unilateral headaches, vague symptoms reminiscent of jaw claudication as well as increasing proximal muscle pain in his upper limbs. The patient did not, however, note any vision changes or neurologic symptoms. The skin lesion to his left temple was clinically consistent with a basal cell carcinoma and he was subsequently referred to a plastic surgeon for surgical resection. In the interim, to investigate his headaches and other symptoms, the patient's family doctor requested a magnetic resonance image of his brain, which noted only age-related changes. Excision of the left temple lesion revealed an ulcerating basal cell carcinoma (Figure 1), clear of the surgical margins of resection. In addition, a portion of presumed temporal artery noted at the periphery of the primary lesion showed mural-based granulomatous inflammation associated with fibrinoid necrosis obliterating the internal and external arterial elastic laminae (Figure 2). The case was diagnosed as left temple basal cell carcinoma with concomitant giant cell arteritis. The patient received immediate steroid therapy and is well after 2 years of follow-up.
Figure 1
Figure 1
Low-power photomicrograph demonstrating basal cell carcinoma component (top left) with underlying giant-cell arteritis (bottom right) (Hematoxylin and Eosin, 20×).
Figure 2
Figure 2
A) Basal cell carcinoma (Hematoxylin and Eosin, 40×); B) giant-cell arteritis (Hematoxylin and Eosin, 100×); C) giant-cell arteritis (Elastic Van-Gieson, 100×).
GCA is a systemic granulomatous arteritis and may involve large and medium sized arteries from the aortic arch to the scalp.1 Giant cell arteritis is a descriptive histologic diagnosis for a spectrum of rheumatologic entities with similar histological features.2 We were able to note only one other such instance of a reported concurrent basal cell carcinoma with underlying giant cell arteritis; in the former case, however, high clinical suspicion of temporal arteritis was the primary indication for biopsy and the overlying basal cell carcinoma was not ulcerated.11 A review of the English language literature notes a number of individual case reports and case series of GCA occurring in association with a malignancy. GCA has been identified in association with tongue squamous cell carcinoma.12 A report of an invasive ductal carcinoma of the breast with concomitant breast-limited GCA was also noted.13 In a study of 35,918 patients hospitalized for treatment of GCA (either diagnosed with PMR or TA), 3941 patients developed subsequent cancer; the authors noted that this translated to a 19% increased incidence of cancer in patients with GCA relative to controls with a notable increased risk of skin cancer and acute myeloid leukemia.6 In another study of 271 patients diagnosed with GCA by Liozon et al., subsequent malignancy was noted in 20 patients.14 In this study, the reported average time from diagnosis of GCA to detection of malignancy was 3.5 years and the malignant diagnoses were also predominantly hematolymphoid (45% of cases), though cancers of the gastrointestinal tract were also noted.14 This study led the authors to suggest that some malignancies may act as precipitants of TA.
In contrast, a number of other studies have disputed the claims of an association between GCA and malignancy. Hill el al studied 226 cases of biopsy-proven GCA and noted that only 31 cases were diagnosed with cancer subsequent to their diagnosis of GCA; they concluded no increased risk for malignancy in subjects with biopsy-proven GCA relative to the general population.10 In another study, Gonzales-Gay reviewed the medical records of 255 patients with biopsy-proven GCA and noted only a slight increased incidence of cancer in this cohort, without any evidence of worsened cancer-related mortality.7 Finally, Kermani et al. performed a population-based case–control study including 204 GCA cases and 407 controls and noted that GCA patients had no overall increased incidence of cancer, and comparable mortality rates due to cancer relative to the control group.8
GCA is believed to be immunologically mediated.1,2 Some malignancies have been noted to cause systemic immune dysregulation.15 These observations may account for the contradictions noted pertaining to the correlation between GCA and cancer. In particular, as Stern argues,16 both cancer and GCA can produce similar a myalgic clinical picture; clinical bias, therefore, may erroneously draw associations between GCA and malignancy. It should be noted, however, that both malignancies and GCA are diseases showing a predilection for older age groups and thus,17 despite the contradictory data regarding a possible association between GCA and malignancies, it is incumbent on the surgical pathologist to diligently examine all histologic sections in either context to ensure that the other entity is not present concomitantly. Failure to identify GCA in a biopsy to examine a lesion suspicious for malignancy, or vice versa, can put the patient at a significant risk of improper management.18–20
References
1. Langford CA, Fauci AS. Longo DL, Fauci AS, Kasper DL, et al. Harrison's principles of internal medicine. 18th ed. New York: McGraw-Hill; 2012. The Vasculitis Syndromes.
2. Paget SA, Spiera RF. Goldman L, Ausiello D. Cecil Medicine. 23rd Ed. Philadelphia, PA: Saunders Publishing; 2008. Polymyalgia rheumatica and temporal arteritis; pp. 2059–2062.
3. Dummer W, Zillikens D, Schulza A, et al. Scalp necrosis in temporal (giant cell) arteritis: implications for the dermatologic surgeon. Clin Exp Dermatol. 1996;21:154–154. [PubMed]
4. Myklebust G, Gran JT. A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis. Br J Rheumatol. 1996;35:1161–8. [PubMed]
5. Haugeberg G, Dovland H, Johnsen V, et al. Increased frequency of malignancy found in patients presenting with new-onset polymyalgic symptoms suggested to have polymyalgia rheumatica. Arthritis Rheum. 2002;47:346–8. [PubMed]
6. Ji J, Liu X, Sundquist K, et al. Cancer risk in patients hospitalized with polymyalgia rheumatica and giant cell arteritis: a follow-up study in Sweden. Rheumatology (Oxford) 2010;49:1158–63. [PubMed]
7. Gonzales-Gay MA, Lopez-Diaz MJ, Martinez-Lado L, et al. Cancer in biopsy-proven giant cell arteritis. A population-based study. Semin Arthritis Rheum. 2007;37:156–63. [PubMed]
8. Kermani TA, Schafer VS, Crowson CS, et al. malignancy risk in patients with giant cell arteritis: a population-based cohort study. Arthritis Care Res. 2010;62:149–54. [PMC free article] [PubMed]
9. Myklebust G, Wilsgaard T, Jacobsen BK, et al. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol. 2002;29:2143–7. [PubMed]
10. Hill CL, Cole A, Rischmueller M, et al. Risk of cancer in patients with biopsy-proven giant cell arteritis. Rheumatology. 2010;49:756–9. [PubMed]
11. Leboit PE, Davis-Reed L. Light microscopy: clues to system disease in reexcision specimens of basal cell carcinoma. Am J Dermatopathol. 1999;21:361–4. [PubMed]
12. Misselevitch I, Fradis M, Podoshin L, et al. Giant cell arteritis of the tongue associated with squamous cell carcinoma. J Clin Pathol. 1989;42:1001–1001. [PMC free article] [PubMed]
13. Kafantari E, Sotiropoulou M, Sfikakis P, et al. Giant cell arteritis of the breast and breast cancer: paraneoplastic manifestation or concomitant disease? A case report. Onkologie. 2008;31:685–8. [PubMed]
14. Liozon E, Loustaud V, Fauchais AL, et al. Concurrent temporal (giant cell) arteritis and malignancy: report of 20 patients with review of the literature. J Rheumatol. 2006;33:1606–14. [PubMed]
15. Block MS, Markovic SN. The tumor/ immune interface: clinical evidence of cancer immunosurveillance, immunoediting and immunosubversion. Am J Immunol. 2009;5:29–49.
16. Stern R. Giant cell arteritis. New Engl J Med. 1991;324:496–496. [PubMed]
17. Hayreh SS. Hayreh SS. Ischemic optic neuropathies. Berlin: Springer Publishing; 2011. General characteristics of giant cell arteritis; pp. 163–172.
18. Telfer NR, Colver GB, Bowers PW. Guidelines for the management of basal cell carcinoma. Br J Dermatol. 1999;141:415–23. [PubMed]
19. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008;372:234–45. [PubMed]
20. Hernandez-Rodriguez J, Cid MC, Lopez-Soto A, et al. Treatment of polymyalgia rheumatica: a systematic review. Arch Intern Med. 2009;169:1839–50. [PubMed]
Articles from Rare Tumors are provided here courtesy of
PAGEPress